key: cord-0806922-iz1yqmh9
authors: Stoy, Nicholas
title: Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19
date: 2021-04-07
journal: Front Immunol
DOI: 10.3389/fimmu.2021.638446
sha: 05d001ba16f6a626e08539417f328a183e9baa96
doc_id: 806922
cord_uid: iz1yqmh9

Interleukin-1 receptor-associated kinase 4 (IRAK4) and interferon regulatory factor 5 (IRF5) lie sequentially on a signaling pathway activated by ligands of the IL-1 receptor and/or multiple TLRs located either on plasma or endosomal membranes. Activated IRF5, in conjunction with other synergistic transcription factors, notably NF-κB, is crucially required for the production of proinflammatory cytokines in the innate immune response to microbial infection. The IRAK4-IRF5 axis could therefore have a major role in the induction of the signature cytokines and chemokines of the hyperinflammatory state associated with severe morbidity and mortality in COVID-19. Here a case is made for considering IRAK4 or IRF5 inhibitors as potential therapies for the “cytokine storm” of COVID-19.

Effective treatments are required for COVID-19 hyperinflammatory syndrome, occurring characteristically 7-14 days after first symptoms (1) and variously described as "macrophage activation syndrome" (2) , "cytokine storm" (3) or "acute respiratory distress syndrome" (4) . Its immunological hallmarks are excessive elevation of predominantly proinflammatory cytokines, chemokines (5) , and other bioactive molecules, such as HMGB1 (6) and reactive oxygen species (7) . Upregulated cytokines include IL-6, TNF-α, IFN-γ, IL-1β, IL-15, IL-23, and IL-10, and chemokines, CXCL8(IL-8), CXCL9(MIG), CXCL10(IP10), CCL2(MCP-1), CCL3(MIP-1α), CCL5(RANTES), CCL7(MCP-3), CCL8(MCP-2), CCL11(eotaxin-1), and CCL20(MIP-3α) (1, 2, (8) (9) (10) (11) . This review examines the role of IRAK4 and IRF5 in the evolution and modulation of the immune response to SARS-CoV-2 and whether IRAK4 or IRF5 inhibitors could have a role in treating the hyperinflammatory phase (12) (13) (14) .

IRAK4, recruited with other binding partners to MYD88 (Figure 1 ) forms the myddosome (14) (15) (16) , which is activated by ligands of the IL-1 receptor or TLRs that bind MYD88 (13, 17, 18) . IRAK4 is recruited to the complex with IRAK1 and TRAF6 (19) . On receptor activation IRAK4 homodimerizes, autophosphorylates and subsequently phosphorylates IRAK1 (20-22). These kinases are ultimately responsible for activation of IRF5, requiring phosphorylation of critical C-teminal serines (23, 24). Another component of IRF5 activation is its K63polyubiquitination by TRAF6 (25, 26). The inducible (and IRAK1-phosphorylated) ubiquitin ligase Pellino-1, with E2-conjugating enzymes (27), reciprocally K63polyubiquinates both IRF5 and IRAK1/4 but, conversely, kinase-active IRAK1/4 mediates degradative polyubiquitination of Pellino-1 (27-29). Distal to the myddosome the signaling pathway bifurcates into IRF5-and NF-κB-activating branches (30). At commencement of the IRF5 branch, activated IRAK4/IRAK1 phosphorylates the kinase TAK1 (31), which in turn phosphorylates IKKβ (24, 32); finally, IKKβ phosphorylates IRF5 (33, 34) facilitating its dimerization and translocation to the nucleus (35). Whereas, IKKβ is the archetypal kinase activator of NF-κB by phosphorylating IκBα, it is important to appreciate that kinase activity of IRAK4 is not essential for NF-κB activation by the myddosome route (35); however, this does not preclude an IRAK4 scaffolding function (20). Crucially, therefore, blocking IRAK4 with a specific kinase inhibitor abolishes IRF5 activation but still permits NF-κB activation by other means, either by IKKβ itself via this or other signaling pathways (31), or using other kinases such as a MEKK3-dependent pathway (17, 30, 35, 36). Speculatively, endosomal TLR3, responsive to dsRNA, may signal independently of MYD88 to IRF5 through TRAF6 using the adaptor TRIF (as well as to IRF3/7 via TRAF3) and may synergise with other TLRs (37, 38, 183); TLR4, translocated to endosomes, may also signal using TRAM-TRIF instead of MYD88 (19, (39) (40) (41) 183) . IRF5 homodimers complex with CBP/p300 to initiate the IRF5 transcriptome synergistically with NF-κB (42, 43).

Activation of IRF5 is tightly controlled. Inducible IRAK-M inhibits assembly of the IRAK1-IRAK4-TRAF6 complex both directly, and indirectly by induced negative feedback (44-46); Lyn kinase, in dendritic cells (DCs), binds IRF5, inhibiting its K63polyubiquitination and phosphorylation, but not affecting the NF-κB branch (47); IRF8 competes with IRF5 at promoters, blocking its action (48, 49); and KAP1/TRIM28 is an IRF5 transcriptional co-repressor (50). TLRS 7-9 require at least two adapter proteins, TASL and SLC15A4, at the endosomal membrane, to engage the IRAK4-IRF5 pathway (51).

In responding to viruses, activated IRF5 homodimers bind with low affinity to "viral response elements" inducing primarily IFNA type I interferons (52). However, IRF5 binds strongly to the regulatory loci of other IRF5-targetted genes, such as IFNB, CXCL10, IL-10 (52), IL-12, and IL-23 (53), although in the case of anti-inflammatory IL-10, IRF5 is not directly responsible for its elevation in "cytokine storm, " being inhibitory at the IL-10 promoter (53, 54). Mechanistically, a challenging complexity of variables influence IRAK4-IRF5 pathway activation outcomes (55) : these include different IRF5 dimerization partners-including homodimerization and IRF7 (56) ; functionally different IRF5 isoforms, as investigated in plasmacytoid DCs (pDCs) (57); IRF5 interacting with different transcription factors (17), most critically the NF-κB subunits, p50 (48, 58) , and/or p65(RELA) (41, 59, 60); different cellular localizations, notably monocytes, macrophages, pDCs, and B cells (55, 58, 61) ; different triggers of pathway activation, for e.g., viral infection or autoimmunity; inhibition of the IRF5mediated activation of IFN-β by the IKKα pathway (62) ; and differences between murine and human cells (63)-all beyond the scope of this review. Nevertheless, despite these many complicating factors, the IRAK4-IRF5 axis consistently polarizes monocytes/macrophages toward the proinflammatory M1 (49, 53, 64) phenotype, displaying a similar innate cytokine/chemokine profile as in "cyokine storm" and indicating a potential therapeutic role for IRAK4 or IRF5 inhibition.

A proinflammatory response is characteristic of the innate immune system's reaction to microbial infection. Endotoxin tolerance in monocytes blunts this response by interfering with recruitment and activation of IRAK4 at the MYD88 receptor complex, inhibiting K63polyubiquitination of IRAK1 and TRAF6, and compromising IRAK1-TRAF6 function and TAK1 activation (65) . Mice lacking IRAK4 exhibit deficient IL-1 and TLR signaling, are resistant to LPS and cannot induce TNF-α or IL-6 (17, 66, 67) . The IRAK4 inhibitor, chlorogenic acid, extracted from lonicerae flos, protects mice from endotoxic shock: chlorogenic acid inhibits autophosphorylation of IRAK4 in peritoneal macrophages subjected to various activating stimuli, including ssRNA, IL-1α, or HMGB1 (6, 68, 69). Inhibition of IRAK4 or IRF5 downregulates the proinflammatory IRF5 transcriptome independently of NF-κB activation (35). In the same way that endotoxic shock is abrogated by inhibiting IRF5, "cytokine storm" in viral infection can also be suppressed by IRF5 inhibition, as shown for influenza A (26, 70). Thus, IRF5 inhibition protects from hyperinflammation whether induced by viral or bacterial infection, the latter a common complication of acute respiratory distress syndrome, although its incidence in COVID-19 is only just being investigated (71) (72) (73) 184) . Figure 2 summarizes how SARS-CoV-2 innate immune activation is linked to specific T cell (cytotoxic and memory) and B cell (antibody) adaptive immune responses, comprising the substantive immunological reaction necessary for viral elimination (53, 54). COVID-19 immunopathogenesis divides conveniently into three overlapping interactive phases with sequential involvement of epithelial cells, innate immune cells and adaptive immune cells. Nasal and alveolar type II epithelial cells express high levels of ACE2, the SARS-CoV-2 entry receptor, and respond first. Epithelial immune activation is mediated by IRF3 phospho-dimerisation, with a lesser contribution from IRF5 phospho-dimerization, and NF-κB p65 as coactivator FIGURE 2 | With burgeoning knowledge of immune cell phenotypes in COVID-19, particularly from single-cell transcriptomics, and despite much heterogeneity amongst T-cell clusters, it is now possible to attempt a broad generalization of (at least some) changes in innate and adaptive immunity during COVID-19 progression. In this schematic representation, a suppressed type I interferon response in epithelial cells, IRF5-dependent proinflammatory macrophage and DC polarization, and an (Continued)

Frontiers in Immunology | www.frontiersin.org 4 April 2021 | Volume 12 | Article 638446 FIGURE 2 | inadequate adaptive response are three sequential major drivers of COVID-19 immunopathogenesis. The accompanying table is a tentative interpretation of some of the (sometimes conflicting) features of the immune cell phenotypic landscape of "cytokine storm" (1, 2, (9) (10) (11) (157) (158) (159) (160) (161) (162) (163) . SARS-CoV-2 can be taken up by macrophages and DCs but does not proliferate, whilst the highly variable type I IFN response from each individual cell likely depends on temporal sequencing and integration of inputs both from viral components and from other non-viral inputs (TLR and/or cytokine), either synergistic or separate (179) (180) (181) (182) (183) . Key: +signs indicate changes in immune cell parameters associated with "cytokine storm" and black vertical arrows indicate changes from the expected normal immune response. IRF5 appears to be widely expressed in most immune cells (164) (165) (166) and recently CD4+ and CD8+ intrinsic IRF5 activity has been demonstrated to be responsible for increased secretion of Th1 and Th17 cytokines and for reduced Th2 and T reg cytokines, on T cell activation, as indicated by blue arrows and blue +signs in the table: IRF5 upregulates chemokine receptors CXCR4/5 and CCR6/7/9, on stimulated CD4+ T cells (165, 166) ; the relevance of these observations to COVID-19 pathogenesis is as yet unknown. SLEC: short-lived effector cells; BALF: bronchoalveolar lavage fluid; GC, germinal center. (59, 60, 75) . Critically, the type I interferon component of the epithelial cell proinflammatory response is selectively suppressed by proliferating SARS-CoV-2 (74), so disrupting secondary expression of interferon-stimulated genes (ISGs) including the potent IRF3 dimerisation partner IRF7 (75) . Epithelial cells favor IFN-λ expression but this is a less effective inducer of ISGs than type I interferons (76) . The viral MDA5 RNA-sensor requires kinases TBK1 or IKKε to activate IRF3 (77, 78) ; the same kinases can activate IRF5. By contrast, IKKβ, a strong activator of IRF5, fails to activate IRF3 (61) In phase two, epithelial chemokines attract a large influx of innate immune cells comprising DCs, natural killer (NK) cells and neutrophils (11, (79) (80) (81) ; IRF5 is considered the main orchestrator of this innate response (61) . DCs are pivotal in communicating with the adaptive immune system to initiate phase three: programming of adaptive immunity. Phase three culminates either in viral clearance and COVID-19 resolution or complications such as "cytokine storm, " clotting disorders, cardiovascular complications or multi-organ failure. Involvement of adaptive immunity adds further cytokines to the mix. IL-17, the product of Th-17 cells, is triggered by DCs expressing IL-23 (increased with age). Induction of this and other DC cytokines IL-1β, IL-6, IL-12, and TNF-α is again dependent on IRF5, usually with NF-κB coactivators (53, 58, 59, 61, 82-84). Indeed, recent evidence suggests IRF5 may even vie with IRF7 for the title 'master regulator' , if not of type I interferons, at least of most other DC cytokines (42, 52, 75, 85-88); furthermore, there is mutual inhibition between these two IRFs (56) . Th1 cells are activated by the innate cytokine IL-12 from DCs and secrete IFN-γ, as do NK cells. However, in COVID-19 multifunctional activated T cells secreting two of the three cytokines IFN-γ, IL-2, and TNF-α were reduced whilst T cells producing all three were non-functional (89) . Innate immunity is relatively preserved during aging and constitutively upregulated in many comorbid conditions exacerbating COVID-19, albeit stimulating a defective adaptive response. In aging, pDCs retain most of the proinflammatory phenotype, but type I and type III interferons are impaired (90) , as are interactions with T and B cells for antigen presentation, primarily due to T and B cell dysfunction, exacerbated by SARS-CoV-2 (91). IRF5 is constitutively expressed by pDCs, especially in females who produce more IFN-α on TLR stimulation than males, making dysregulation of immune responses in COVID-19 in females less likely (92, 93) . IRF5-dependent IFN-β expression in DCs is demonstrated in IRF5-knock-out mice, which exhibit poor interferon responses to TLR stimulation or microbial infection (49, 94). Overall, DCs adopt a proinflammatory phenotype on contact with SARS-CoV-2, a tendency exacerbated by increasing age (91, 95) . Cellular correlates of poor outcome in COVID-19 are neutrophilia (3), low CD4+ and CD8+ T cells and general lymphopenia (96, 97) , combined with increased markers of T cell exhaustion (PD-1 and TIM-3) and senescence (CD57) and a specific cytokine signature (10, 73, (98) (99) (100) .

B cells depend on IRF5-induced Blimp-1 for differentiation into plasma cells, responsible for long-lasting antibody immunity (101) . In SARS-CoV-2 "cytokine storm, " B cell function is compromised by reduced total circulating B cells, reduced class switching from IgM to IgG and increased plasmablasts and transitional cells, suggestive of rapid B cell proliferation and exhaustion, probably related to excessive IL-6 and TNF-α (102) .

Platelets are integral components of the immune system. Viruses can enter platelets, activate endosomal TLRs (TLR7/TLR9) and downstream MYD88-IRAK4-IRAK1-IKKβ (and presumably IRF5), possibly contributing to COVID-19 thrombocytopenia and clotting irregularities (103, 104) .

Maintaining the M1 phenotype is energy-consuming and achieved by a "metabolic switch" from oxidative to glycolytic metabolism during M2-to-M1 polarization (41). Viral infections increase glucose metabolism in macrophages, involving activation of the hexosamine biosynthesis pathway and associated enzyme O-GlcNAc transferase, as already proposed for SARS-CoV-2 (105). Thus, increased activation of IRF5 by K63polyubiquitination may turn out to provide an important link between so-called "metabolic inflammation" and increased severity of the cytokine response in COVID-19 (105, 106) . Infection with influenza virus markedly increases GlcNAcylation of IRF5 at serine 430 in human macrophages, which is essential for K63polyubiquitination of the same residue that activates IRF5, thus promoting proinflammatory cytokine expression and possibly increased viral replication (26). Inflammation is a wellrecognized driver of the metabolic syndrome, manifest clinically in obesity, type II diabetes and other conditions in which insulin resistance occurs. Blood sugar instability associates with IRF5 upregulation and M1 phenotype in adipose tissue macrophages, including elevation of the cardiovascular risk factor, matrix metalloproteinase-9. TLR4 is also upregulated and it has even been hypothesized that increased proinflammatory cytokines could be triggered by endogenous TLR4 ligands, presumably through IRAK4-IRF5 signaling (41). IRF5 knock-out mice exhibit improved glucose tolerance and reduced excess body fat. The M1 macrophage cytokine and chemokine profile of adipose tissue in obesity and diabetes, signifying chronic inflammation, is in many respects similar to a muted version of cytokine storm. Thus, adipose IRF5 transcripts in obesity correlate positively with TNF-α, IL-1β, IL-6, CXCL8/IL-8, CXCL9/MIG, CXCL10/IP10, CCL2/MCP1, CCL5, and CCL7/MCP3, all of which can be elevated in COVID-19 "cytokine storm" (107, 108); positive correlations with IL-2 and IL-12 have been reported by the same group. TLR4, TLR7, and TLR8 are increased in obesity and correlate with IRF5 expression, but whether this occurs in SARS-CoV-2 infection is unknown (109, 110) .

There is increased Pellino-1 expression in adipose tissue macrophages in obesity. Pellino-1 exacerbates glucose intolerance in obese mice through K63polyubiquitination of IRF5, promoting M1 macrophage polarization (106); the adverse proinflammatory skewing of innate immunity is further compounded by Pellino-1 inhibition of tolerogenic M2 macrophages by K63polyubiquitination of IRAK1 (111) . Correspondingly, in acute viral respiratory infections, there is an association between elevated Pellino-1 and proinflammatory cytokines (112) .

Chronic innate proinflammatory drive to the adaptive immune system in metabolic inflammation leads eventual to T cell exhaustion. Changes in T and B cell function in metabolic inflammation, as well as in the elderly and, more acutely, in COVID-19 are all broadly similar, in that innate function is relatively preserved, but T cell and B cell compartments exhibit features of "exhaustion" or "senescence" (73, 113, 114) . Therefore, pre-existing metabolic inflammation across a variety of chronic conditions presages an unfavorable course and outcome of COVID-19 (115, 116) .

The well-established paradigm that innate immunity programs adaptive immunity applies not only in microbial infection (117) but also autoimmunity (118, 119) and cancer, being generally tolerogenic in the latter. "Cytokine storm" of COVID-19 illustrates the dangers of a fundamental mismatch between increased proinflammatory innate signaling and a defective adaptive response, insufficient to kill the virus or prevent spread (105), thus failing to abort innate immune activation. This review has presented evidence that IRF5 is a key "hub" molecule determining the normal balance between innate and adaptive immunity. In what clinical situations, therefore, could IRAK4/IRF5 inhibitors have therapeutic benefit?

Many clinical consequences arise from immune system dysregulation in COVID-19. Importantly, for proposed treatment of "cytokine storm" with an IRAK4 inhibitor, timing, and dose titration are critical-too early, too protracted or too high a dose and the natural host immune response is further blunted. It follows that reliable real-time (blood) biomarkers of IRF5-driven immune activation would be essential to determine the threshold for both commencement and termination of treatment (120, 121) . To avoid overdosage, the ideal IRAK4 inhibitor would be quick-acting with short half-life (122, 123) . Amongst candidate COVID-19 inflammation biomarkers is IRF5 itself, raising the possibility of studying this key molecule across the whole range of SARS-CoV-2 infection and associated comorbidities (124, 125) ; already IRF5 is suggested as a novel adipose marker in chronic metabolic inflammation (108) and inflammatory bowel disease (125) .

Another practical issue is management of patients on long-term immuno-suppressants: these drugs could be viewed simplistically as raising the threshold for effective adaptive immune activation, particularly with drugs inhibiting T or B cell function. Nevertheless, it is surmised that many patients could reset their immune response appropriately and experience symptomless or mild COVID-19, but in others, nearer the tipping-point, the chances of hyperinflammatory syndome may be significantly increased. As there is no a priori reason in these patients to suppose increased viral uptake at the onset, the advised management of COVID-19 has continued to be on accepted lines and routine immuno-suppressants continued unless "cytokine storm" becomes imminent (126, 127) .

Similar reasoning may be applied to initial high viral load or prolonged exposure, which could overwhelm adaptive immunity and push the balance toward increased, but less effective, innate immune activation and "cytokine storm." A related unresolved difficulty is management of chronic COVID-19 symptoms, especially if associated with identifiable chronic inflammation, including neurological sequelae (115) . Indeed, the predisposing conditions for hyperinflammatory COVID-19 are likely to overlap with at least some of those responsible for post-infection sequelae. Whether viral persistence occurs is uncertain, but post-infection inflammatory markers suggest ongoing low-grade innate immune activation linked to adaptive immune dysregulation and/or exhaustion (128) . Chronic infection promotes the death of protective CD4+ cells through TLR7 and IRF5 (129) . Thus, in socalled "long COVID" the perceived imbalance of innate and adaptive immunity may be finely poised and potentially amenable to favorable manipulation, conceivably using IRAK4 or IRF5 inhibition.

Dexamethasone, anakinra and tocilizumab are amongst anti-inflammatory drugs already repurposed for treatment of "cytokine storm." Although the extent of dexamethasone interaction with the IRAK4-IRF5 axis is not established, IRAK4/IRF5 inhibitors are still likely to provide a more focused approach than the generalized actions of steroids (130) . On the other hand, IRAK4/IRF5 inhibitors would have a wider spectrum of action than the IL-1 receptor antagonist, anakinra (131, 132) or IL-6 receptor blocker, tocilizumab. Predictably, there is concern that overuse/prolonged use of steroids as immuno-suppressants could suppress viral clearance (133): by contrast, IRAK4 inhibition is potentially steroid-sparing (134) . Latest data indicates significant benefit in severe COVID-19 from tocilizumab, either alone or with dexamethasone (135) (136) (137) . CXCL8/IL-8 inhibitors are being trialed to reduce neutrophil recruitment (138, 139) . However, as proposed here, a better option might be concurrent suppression by just one drug of multiple innate cytokines and chemokines, including IL-1, IL-6 and neutrophil-attractant chemokines (CXCL8 and CXCL5), as would be achievable by an IRAK4 or IRF5 inhibitor. Indeed, in co-cultured RNA-stimulated pDCs and NK cells, IRAK4 inhibition reduced IL-6, CXCL8, CCL3, CCL4, TNF-α, and IFNγ (140), whereas, raised expression of IRF5 (but not IRF3 or IRF7) in kupffer cells and neutrophils in experimental cholestatic jaundice correlated with increased IL-6, TLR4, TLR7, TLR9, HMGB1, CXCL8, and CCL2, with some evidence of steroid reversibility (141) .

Although developed recently, IRAK4 inhibitors are under assessment in psoriasis, whilst in rheumatoid arthritis a completed phase II clinical trial has demonstrated clinical improvement (142) . Interestingly, dimethyl fumarate, already of proven clinical efficacy in treating both multiple sclerosis and psoriasis, is not only a direct inhibitor of IRAK4 but also suppresses innate proinflammatory cytokines in pDCs, providing a strong mechanistic rationale for its recently proposed repurposing for COVID-19 "cytokine storm" (143, 144) . Lowgrade inflammation is common in autoimmunity (145), with an inflammatory signature similar to COVID-19 (146) . The therapeutic usefulness of IRF5 inhibitors is yet to be determined (13, 123, (145) (146) (147) (148) 175) .

Finally, in SARS-CoV-2 vaccine development, an adjuvant stimulating the evolutionary-conserved, IRAK4-IRF5 pathway should be an ideal partner for a SARS-CoV-2 vaccine. IRAK4-IRF5 pathway activators could be included in multi-epitope vaccines (149) . Such formulations should promote optimum immune responses and immunological memory (150) . Suitable targets would be TLR3, TL7, TLR8, or TLR9 (151) (152) (153) .

Paradoxically, even with highly potent vaccines, the adaptive immune system in vulnerable groups may still fail to respond appropriately because risk factors predicting a poor adaptive immune response to vaccination could be the same as those predisposing to COVID-19 "cytokine storm, " although it is yet to be determined whether this will account for a significant fraction of vaccine failures.

In conclusion a caveat: given that IRF5 is essential for normal immunity and that "cytokine storm" in SARS-CoV-2 infection indicates a failure of adaptive immunity to respond appropriately to enhanced (IRF5-mediated) innate signals, it follows that attempts to stop "cytokine storm" by damping down innate immunity should be combined with, or ideally replaced by, effective SARS-CoV-2 virucidal drugs, another high priority in COVID-19 research (154) (155) (156) .

The author confirms being the sole contributor of this work and has approved it for publication. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Macrophage responses associated with COVID-19: a pharmacological perspective

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Management of respiratory distress syndrome due to COVID-19 infection

Chemokines and chemokine receptors during COVID-19 infection

Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 Infection and cytokine shock syndromes

Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider

Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China

The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Immunopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications

Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory-and immune-related disorders

Therapeutic targeting of IRFs: pathway-dependence or structure-based?

Advances and challenges in targeting IRF5, a key regulator of inflammation

Kinase inhibition in autoimmunity and inflammation

Activation and function of interferon regulatory factor 5

Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis

Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes

Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function

IRF-5 and NF-κB p50 co-regulate IFN-β and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells

Interferon regulatory factor 5 and nuclear factor kappa-B exhibit cooperating but also divergent roles in the regulation of pro-inflammatory cytokines important for the development of TH1 and TH17 responses

IRF5:RelA interaction targets inflammatory genes in macrophages

Differential and overlapping immune programs regulated by IRF3 and IRF5 in plasmacytoid dendritic cells

IKKα negatively regulates IRF-5 function in a MyD88-TRAF6 pathway

IRF5, IRF8, and IRF7 in human pDCs -the good, the bad, and the insignificant?

IRF5 is a key regulator of macrophage response to lipopolysaccharide in newborns

Endotoxin tolerance impairs IL-1 receptor-associated kinase (IRAK) 4 and TGFbeta-activated kinase 1 activation, K63-linked polyubiquitination and assembly of IRAK1, TNF receptor-associated factor 6, and IκB kinase gamma and increases A20 expression

Severe impairment of interleukin-1 and toll-like receptor signalling in mice lacking IRAK-4

IL-1R-associated kinase 4 is required for lipopolysaccharide-induced activation of APC

IRAK4 as a molecular target in the amelioration of innate immunity-related endotoxic shock and acute liver injury by chlorogenic acid

HMGB1-C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis

MicroRNA-302a suppresses influenza A virus-stimulated interferon regulatory factor-5 expression and cytokine storm induction

IRF5 is required for bacterial clearance in human M1-polarized macrophages, and IRF5 immunemediated disease risk variants modulate this outcome

Expression levels of interferon regulatory factor 5 (IRF5) and related inflammatory cytokines associated with severity, prognosis, and causative pathogen in patients with community-acquired pneumonia

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

IRFs: master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors

COVID-19: lambda interferon against viral load and hyperinflammation

MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells

IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway

RNA sensors of the innate immune system and their detection of pathogens

Natural killer cell responses to emerging viruses of zoonotic origin

The potential effect of novel coronavirus SARS-CoV-2 on NK Cells; a perspective on potential therapeutic interventions

Myeloid cell-Intrinsic IRF5 promotes T cell responses through multiple distinct checkpoints in vivo, and IRF5 immune-mediated disease risk variants modulate these myeloid cell functions

Aging-dependent upregulation of IL-23p19 gene expression in dendritic cells is associated with differential transcription factor binding and histone modifications

IRF-7 is the master regulator of type-I interferon-dependent immune responses

Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production

IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling

Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon α genes

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Impaired secretion of interferons by dendritic cells from aged subjects to influenza: role of histone modifications

Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome

Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-alpha production in women

Biological sex impacts COVID-19 outcomes

Type I interferon production induced by Streptococcus pyogenesderived nucleic acids is required for host protection

Dendritic cells and aging: consequences for autoimmunity

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)

Immune alterations in a patient with SARS-CoV-2-related acute respiratory distress syndrome

Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients

Critical role of IRF-5 in regulation of B-cell differentiation

Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia

Platelets endocytose viral particles and are activated via TLR (tolllike receptor) signaling

Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID

Working hypothesis for glucose metabolism and SARS-CoV-2 replication: interplay between the hexosamine pathway and interferon RF5 triggering hyperinflammation. Role of BCG vaccine? Front Endocrinol

Cytosolic Pellino-1-mediated K63-linked ubiquitination of IRF5 in M1 macrophages regulates glucose intolerance in obesity

Increased adipose tissue expression of interferon regulatory factor (IRF)-5 in obesity: association with metabolic inflammation

Enhanced adipose expression of interferon regulatory factor (IRF)-5 associates with the signatures of metabolic inflammation in diabetic obese patients

Adipose tissue gene expression of CXCL10 and CXCL11 modulates inflammatory markers in obesity: implications for metabolic inflammation and insulin resistance

Elevated adipose tissue associated IL-2 expression in obesity correlates with metabolic inflammation and insulin resistance

Ubiquitin E3 ligase pellino-1 inhibits IL-10-mediated M2c polarization of macrophages, thereby suppressing tumor growth

Pellino-1 regulates the responses of the airway to viral infection

The impact of body mass index on adaptive immune cells in the human bone marrow

A human circulating immune cell landscape in aging and COVID-19

Implication of aging related chronic neuroinflammation on COVID-19 pandemic

Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19

The longitudinal immune response to Coronavirus Disease 2019: chasing the cytokine storm

Innate origins of multiple sclerosis pathogenesis: implications for computer-assisted design of disease-modifying therapy

B cell-specific loss of lyn kinase leads to autoimmunity

CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS

IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization

IRF5 is a specific marker of inflammatory macrophages in vivo

IRF5 acts as a potential therapeutic marker in inflammatory bowel diseases

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of IL-23

Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection

IRF-5 promotes cell death in CD4 T cells during chronic infection

Dexamethasone or hydrocortisone in COVID-19?

Blocking IL-1 to prevent respiratory failure in COVID-19

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

SARS-CoV-2 and COVID-19: how much do we know?

Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity

Tocilizumab in patients admitted to hospital with covid-19 (Recovery): preliminary results of a randomised, controlled, open-label

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (review)

Re-analysis of single cell transcriptome reveals that the NR3C1-CXCL8-neutrophil axis determines the severity of COVID-19

Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infectioninduced lung inflammatory innate immune response in an in vivo hACE2 transfection mouse model

Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor

Glucocorticoid modulates high-mobility group box 1 expression and tolllike receptor activation in obstructive jaundice

Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis

Dimethyl fumarate disrupts human innate immune signaling by targeting the IRAK4-MyD88 complex

Calming the (cytokine) storm: dimethyl fumarate as a therapeutic candidate for COVID-19

Regulation and role of the transcription factor IRF5 in innate immune responses and systemic lupus erythematosus

Interferon regulatory factor 5 in human autoimmunity and murine models of autoimmune disease

Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections

IRF5 inhibitor shows promise in mouse models of SLE

Designing of nucleocapsid protein based novel multi-epitope vaccine against SARS-COV-2 using immunoinformatics approach

New horizons in adjuvants for vaccine development

Adjuvants for coronavirus vaccines

CpG oligonucleotides as vaccine adjuvants

Recent advances in the discovery and delivery of TLR7/8 agonists as vaccine adjuvants

Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity -opportunity for repurposed chemotherapy of COVID-19 infection

Cytokine storm may not be the chief culprit for the deterioration of COVID-19

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

Singlecell landscape of immunological responses in patients with COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing

Dynamics of NK, CD8 and Tfh cell mediated the production of cytokines and antiviral antibodies in Chinese patients with moderate COVID-19

Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T cells in COVID-19

Deficiency of Tfh cells and germinal center in deceased COVID-19 patients

Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19

Inhibition of IRF5 hyperactivation protects from lupus onset and severity

T Cell-intrinsic IRF5 regulates T cell signaling, migration, and differentiation and promotes intestinal inflammation

Potential T cell-Intrinsic regulatory roles for IRF5 via cytokine modulation in T helper subset differentiation and function

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality

Macrophage alterations in islets of obese mice linked to beta cell disruption in diabetes

Viral activation of interleukin-15 (IL-15): characterization of a virusinducible element in the IL-15 promoter region

Cutting edge: the role of IFN-alpha receptor and MyD88 signaling in induction of IL-15 expression in vivo

IL-15 up-regulates the MMP-9 expression levels and induces inflammatory infiltration of macrophages in polymyositis through regulating the NF-κB pathway

The hyperferritinemic syndrome: macrophage activation syndrome, Still'sdisease, septic shock and catastrophic antiphospholipid syndrome

The role of the IL-33/ST2 immune pathway in autoimmunity: new insights and perspectives

IRF5 controls both acute and chronic inflammation

Neutrophil extracellular traps induce tissue-invasive monocytes in granulomatosis with polyangiitis

IRF5 guides monocytes toward an inflammatory CD11c(+) macrophage phenotype and promotes intestinal inflammation

Viral infection and toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

A dynamic COVID-19 immune signature includes associations with poor prognosis

Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis

Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients

TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation

Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome. medRxiv

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2021 Stoy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.